Comparative pharmacology of low molecular weight heparins: implications of manufacturing processes on biological effects.
With the recent development of numerous low molecular weight heparins (LMWHs), a certain amount of concern has become evident as to the equivalency of each agent. In a comprehensive study, we have taken the seven available LMWHs to directly compare their in vitro and in vivo (subcutaneous) antithrombotic properties in one laboratory setting. Where possible, various batches of one LMWH were evaluated. Our findings were that variations of in vivo activity were observed between the LMWHs studied. Some activities were significantly different from placebo, whereas others were not. Depending on the assay chosen significant differences could also be observed for the in vitro activity.
Doutremepuich
C
C
Université de Bordeaux II, Faculté de Pharmacie, France.
Guyot
M
M
Lalanne
M C
MC
Deharo
E
E
Walenga
J M
JM
Fareed
J
J
D000818:Animals; D004339:Drug Compounding; D065427:Factor Xa Inhibitors; D005342:Fibrinolysis / Q000187:drug effects*; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology* / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D008297:Male; D008970:Molecular Weight; D010314:Partial Thromboplastin Time; D051381:Rats; D011919:Rats, Inbred Strains; D013329:Structure-Activity Relationship; D013918:Thrombin Time; D013924:Thrombophlebitis / Q000188:drug therapy*
D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight